Screener
BioMarin Pharmaceuticals BMRN Total Revenue
Total Revenue at other companies
Segments
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| REVENUES: | ||||
| Net product revenues | $984,393 | $812,982 | $1,744,471 | $1,547,626 |
| Royalty and other revenues | 5,315 | 12,428 | 11,445 | 22,929 |
| Total revenues | 989,708 | 825,410 | 1,755,916 | 1,570,555 |
| OPERATING EXPENSES: | ||||
| Cost of sales | 202,795 | 150,090 | 397,794 | 301,648 |
| Research and development | 206,952 | 161,308 | 385,748 | 320,039 |
| Selling, general and administrative | 395,549 | 232,279 | 653,839 | 438,395 |
Item 1. Financial Statements
FAQ
- What is BioMarin Pharmaceuticals's total revenue?
- BioMarin Pharmaceuticals (BMRN) reported total revenue of $989.71M in Q2 2026.
- How has BioMarin Pharmaceuticals's total revenue changed year-over-year?
- BioMarin Pharmaceuticals's total revenue increased by 19.9% year-over-year, from $825.41M to $989.71M.
- What is the long-term trend for BioMarin Pharmaceuticals's total revenue?
- Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's total revenue has grown at a 14.9% compound annual growth rate (CAGR), from $1.85B to $3.22B.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about BioMarin Pharmaceuticals's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude